Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2014—Inova Diagnostics announced the global launch of Quanta Lite Calprotectin, an FDA-cleared, quantitative ELISA that detects calprotectin levels, aids in the diagnosis of inflammatory bowel disease, and can also help differentiate, in conjunction with other laboratory and clinical findings, IBD from irritable bowel syndrome.
August 2014—Biocare Medical was issued a patent from the U.S. Patent and Trademark Office for its PIN-4 (CK5/14 + P63 + P504S) multiplex immunohistochemistry technology.
August 2014—PepFinder, from Thermo Fisher Scientific, is a software tool that streamlines relative and absolute quantitation and identification of proteins from biological samples using liquid chromatography-mass spectrometry.
August 2014—Ventana Medical Systems launched three robust prototype assays for the detection of biomarkers PSMA (prostate specific membrane antigen), MDM2 (mouse double minute 2), and FGFR (fibroblast growth factor receptor 2).
August 2014—Thermo Fisher Scientific’s refrigerated small benchtop centrifuges separate samples in a compact footprint and run a wide range of applications. The refrigeration system provides a temperature range of -10°C to -40°C and can maintain temperatures when the chamber is not in use.
August 2014—HTG Molecular Diagnostics announced the availability of HTG EdgeSeq miRNA Whole Transcriptome Assay for measuring the expression of 2,275 human microRNAs described in the miRBase v20 database.
August 2014—Streck added markers to CD-Chex CD117 Plus, a commercially available positive procedural control for CD117, and now CD25 and CD71. CD-Chex 117 Plus eliminates the need for laboratories to hold and validate patient samples to use as a control for CD117, CD25, and CD71.
August 2014—Two veteran public relations consultants, Ryan Fitzgerald and Chuck Weber, have formed Prefix Public Relations, which offers a unique value proposition: clients pay fixed-price fees for ongoing programs and services instead of hourly charges.
August 2014—The Clinical and Laboratory Standards Institute published H52-A2—Red Blood Cell Diagnostic Testing Using Flow Cytometry; Approved Guideline—Second Edition. This standard addresses the diagnostic red blood cell assays performed as fluorescence-based assays on a flow cytometry platform, including testing procedures for fetomaternal hemorrhage detection, paroxysmal nocturnal hematuria screening, membrane defect anemia testing for hereditary spherocytosis, and nucleated RBC counting. Caveats of interpretation and points of validation and quality control are also discussed.
August 2014—Curetis announced that Robin Patel, MD, professor of medicine and microbiology at Mayo Clinic in Rochester, Minn., has been named lead principal investigator of the company’s Unyvero LRT Application FDA trial.
